Literature DB >> 33446143

Tumor infiltrating neutrophil might play a major role in predicting the clinical outcome of breast cancer patients treated with neoadjuvant chemotherapy.

Sheng-Kai Geng1, Shao-Mei Fu2, Shi-Hong Ma1, Yi-Peng Fu3, Hong-Wei Zhang4.   

Abstract

BACKGROUND: This study was aimed to explore the predictive ability of tumor infiltrating neutrophil (TIN) in patients with breast cancer treated with neoadjuvant chemotherapy (NACT). Furthermore, the significance of TIN's dynamic change before and after NACT was investigated.
METHODS: Between January 2004 and December 2017, a total of 133 patients with breast cancer who underwent NACT before surgery were enrolled in this retrospective cohort. Eighty-nine of them were able to get the core needle biopsy (CNB) samples and all the pathological samples after surgery were available. TIN was detected by immunohistochemical staining of CD66b. The optimal cut-off value was determined via receiver operating characteristic (ROC) curve analysis. The association of clinicopathologic characteristics and chemotherapy efficiency was analyzed using X2 test or Fisher's exact test or t-test as appropriate, and the prognostic significances were assessed by univariate and multivariate analyses.
RESULTS: Patients with higher TIN after NACT were confirmed to be significantly associated with worse prognosis (P = 0.002). After stratifying patients into two groups, high difference group was prone to have better chemotherapy efficiency (P < 0.001) and clinical outcome in both univariate (P = 0.002) and multivariate analyses (P = 0.003).
CONCLUSIONS: In this study, higher TIN after NACT was confirmed to be associated with breast cancer patients' worse chemotherapy efficiency and shorter disease-free survival (DFS). Furthermore, the TIN's dynamic change before and after NACT was firstly proved to be a more accurate predictive marker compared with TIN after NACT.

Entities:  

Keywords:  Breast cancer; Chemotherapy efficiency; Disease-free survival; Neoadjuvant chemotherapy; Tumor infiltrating neutrophil

Mesh:

Substances:

Year:  2021        PMID: 33446143      PMCID: PMC7809871          DOI: 10.1186/s12885-021-07789-6

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


  34 in total

Review 1.  Tumor-associated neutrophils: new targets for cancer therapy.

Authors:  Alyssa D Gregory; A McGarry Houghton
Journal:  Cancer Res       Date:  2011-03-22       Impact factor: 12.701

2.  A long-term retrospective comparative study of the oncological outcomes of 598 very young (≤35 years) and young (36-45 years) breast cancer patients.

Authors:  András Szollár; Mihály Újhelyi; Csaba Polgár; Edit Oláh; Dávid Pukancsik; Gábor Rubovszky; Nóra Udvarhelyi; Tibor Kovács; Ákos Sávolt; István Kenessey; Zoltán Mátrai
Journal:  Eur J Surg Oncol       Date:  2019-06-05       Impact factor: 4.424

3.  Tumor-infiltrating Neutrophils is Prognostic and Predictive for Postoperative Adjuvant Chemotherapy Benefit in Patients With Gastric Cancer.

Authors:  Heng Zhang; Hao Liu; Zhenbin Shen; Chao Lin; Xuefei Wang; Jing Qin; Xinyu Qin; Jiejie Xu; Yihong Sun
Journal:  Ann Surg       Date:  2018-02       Impact factor: 12.969

Review 4.  RECIST - learning from the past to build the future.

Authors:  Saskia Litière; Sandra Collette; Elisabeth G E de Vries; Lesley Seymour; Jan Bogaerts
Journal:  Nat Rev Clin Oncol       Date:  2016-12-20       Impact factor: 66.675

5.  Peripheral blood neutrophil granulocytes from patients with head and neck squamous cell carcinoma functionally differ from their counterparts in healthy donors.

Authors:  S Trellakis; H Farjah; K Bruderek; C A Dumitru; T K Hoffmann; S Lang; Sven Brandau
Journal:  Int J Immunopathol Pharmacol       Date:  2011 Jul-Sep       Impact factor: 3.219

6.  High expression of macrophage colony-stimulating factor-1 receptor in peritumoral liver tissue is associated with poor outcome in hepatocellular carcinoma after curative resection.

Authors:  Jin-Bin Jia; Wen-Quan Wang; Hui-Chuan Sun; Xiao-Dong Zhu; Liang Liu; Peng-Yuan Zhuang; Ju-Bo Zhang; Wei Zhang; Hua-Xiang Xu; Ling-Qun Kong; Lu Lu; Wei-Zhong Wu; Lu Wang; Zhao-You Tang
Journal:  Oncologist       Date:  2010-06-15

7.  Occurrence and significance of tumor-associated neutrophils in patients with colorectal cancer.

Authors:  Maria Rosaria Galdiero; Paolo Bianchi; Fabio Grizzi; Giuseppe Di Caro; Gianluca Basso; Andrea Ponzetta; Eduardo Bonavita; Marialuisa Barbagallo; Silvia Tartari; Nadia Polentarutti; Alberto Malesci; Gianni Marone; Massimo Roncalli; Luigi Laghi; Cecilia Garlanda; Alberto Mantovani; Sébastien Jaillon
Journal:  Int J Cancer       Date:  2016-03-24       Impact factor: 7.396

8.  Cancer statistics in China, 2015.

Authors:  Wanqing Chen; Rongshou Zheng; Peter D Baade; Siwei Zhang; Hongmei Zeng; Freddie Bray; Ahmedin Jemal; Xue Qin Yu; Jie He
Journal:  CA Cancer J Clin       Date:  2016-01-25       Impact factor: 508.702

Review 9.  Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.

Authors:  Robert D Schreiber; Lloyd J Old; Mark J Smyth
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728

10.  Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer.

Authors:  N R West; S E Kost; S D Martin; K Milne; R J Deleeuw; B H Nelson; P H Watson
Journal:  Br J Cancer       Date:  2012-11-20       Impact factor: 7.640

View more
  2 in total

Review 1.  Zebrafish-An Optimal Model in Experimental Oncology.

Authors:  Iwona Kwiatkowska; Justyna Magdalena Hermanowicz; Zaneta Iwinska; Krystyna Kowalczuk; Jolanta Iwanowska; Dariusz Pawlak
Journal:  Molecules       Date:  2022-06-30       Impact factor: 4.927

Review 2.  Intratumoral pro-oxidants promote cancer immunotherapy by recruiting and reprogramming neutrophils to eliminate tumors.

Authors:  Stephen John Ralph; Maxwell J Reynolds
Journal:  Cancer Immunol Immunother       Date:  2022-08-17       Impact factor: 6.630

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.